266 related articles for article (PubMed ID: 12127317)
1. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
[TBL] [Abstract][Full Text] [Related]
2. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies.
Johnston A; Uren E; Johnstone D; Wu J
Biologicals; 2003 Sep; 31(3):213-21. PubMed ID: 12935811
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.
Remington KM; Trejo SR; Buczynski G; Li H; Osheroff WP; Brown JP; Renfrow H; Reynolds R; Pifat DY
Vox Sang; 2004 Jul; 87(1):10-8. PubMed ID: 15260817
[TBL] [Abstract][Full Text] [Related]
5. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of lipid enveloped viruses by octanoic Acid treatment of immunoglobulin solution.
Dichtelmüller H; Rudnick D; Kloft M
Biologicals; 2002 Jun; 30(2):135-42. PubMed ID: 12127315
[TBL] [Abstract][Full Text] [Related]
7. Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate.
Roberts PL; Dunkerley C
Vox Sang; 2003 Apr; 84(3):170-5. PubMed ID: 12670365
[TBL] [Abstract][Full Text] [Related]
8. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography.
Lebing W; Remington KM; Schreiner C; Paul HI
Vox Sang; 2003 Apr; 84(3):193-201. PubMed ID: 12670368
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of lipid-enveloped viruses in proteins by caprylate.
Lundblad JL; Seng RL
Vox Sang; 1991; 60(2):75-81. PubMed ID: 2031341
[TBL] [Abstract][Full Text] [Related]
10. Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS.
Biesert L; Suhartono H
Vox Sang; 1998; 74 Suppl 1():207-12. PubMed ID: 9789530
[TBL] [Abstract][Full Text] [Related]
11. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G
Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061
[TBL] [Abstract][Full Text] [Related]
12. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
[TBL] [Abstract][Full Text] [Related]
13. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
14. Large-scale purification of high purity α1-antitrypsin from Cohn Fraction IV with virus inactivation by solvent/detergent and dry-heat treatment.
Huangfu C; Zhang J; Ma Y; Jia J; Li J; Lv M; Ma X; Zhao X; Zhang J
Biotechnol Appl Biochem; 2018 May; 65(3):446-454. PubMed ID: 29072333
[TBL] [Abstract][Full Text] [Related]
15. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
16. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
17. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma.
Horowitz B; Lazo A; Grossberg H; Page G; Lippin A; Swan G
Vox Sang; 1998; 74 Suppl 1():203-6. PubMed ID: 9789529
[TBL] [Abstract][Full Text] [Related]
18. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.
Bos OJ; Sunyé DG; Nieuweboer CE; van Engelenburg FA; Schuitemaker H; Over J
Biologicals; 1998 Dec; 26(4):267-76. PubMed ID: 10403030
[TBL] [Abstract][Full Text] [Related]
19. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
[TBL] [Abstract][Full Text] [Related]
20. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
Roberts PL; Lloyd D; Marshall PJ
Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
